EUVIMEDEUVIMED entdecken
Crossref

The 2023 FIGO staging system in uterine serous carcinoma: Exploring prognostic utility and molecular characterization

Jiang Meng iD, Li Ge, Xiaoli Wang, Zhicheng Yu, Ping Cheng, Maolin Yang, Jie Li, Dabao Wu, Ying Zhou iD, Jing Zhu, Zhengzheng Chen, Ying Peng und 2 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Jiang Meng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Tec…. Hauptthemen laut MEDLINE: Cystadenocarcinoma, Serous, Uterine Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the prognostic performance of the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system in Chinese uterine serous carcinoma (USC) patients and defined the disease's molecular landscape. Retrospective analysis classified USC patients by both 2009 and 2023 FIGO systems; staging migration was analyzed via cross‐tabulation and Sankey diagrams. Molecular classification used the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) algorithm, with human epidermal growth factor receptor 2 (HER2) expression assessed by immunohistochemistry (IHC). Progression‐free survival (PFS) and overall survival (OS) were analyzed with Kaplan–Meier curves and log‐rank tests; the 2023 system's prognostic ability was validated via time‐dependent receiver operating characteristic (ROC) curves, Harrell's C‐index, and Akaike's Information Criterion (AIC). The 2023 system induced significant staging migration, mainly from IA/IB to IC (endometrium‐confined tumors) or IIC (myometrial invasion). This reclassification achieved better prognostic stratification, shown by higher C‐index and lower AIC than the 2009 system. Molecular profiling clarified subtype distribution, and HER2 overexpression was confirmed in substantial subsets, highlighting therapeutic relevance. The 2023 FIGO staging system provides superior prognostic stratification for Chinese USC patients compared to the 2009 version.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystadenocarcinoma, SerousUterine NeoplasmsHumansFemaleNeoplasm StagingPrognosisRetrospective StudiesMiddle AgedErb-b2 Receptor Tyrosine KinasesAgedBiomarkers, TumorKaplan-Meier Estimate

Stichwörter der Autor:innen

2023 FIGO staging systemHER2molecular classificationprognosisuterine serous carcinoma

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Department of Pathology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
  • Graduate School, Bengbu Medical University, Bengbu, China.
  • Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.

ORCID-Profile: Jiang Meng, Ying Zhou

Zitieren

APA

Meng, J., Ge, L., Wang, X., Yu, Z., Cheng, P., Yang, M., Li, J., Wu, D., Zhou, Y., Zhu, J., Chen, Z., Peng, Y., Li, Y., & Zhao, W. (2026). The 2023 FIGO staging system in uterine serous carcinoma: Exploring prognostic utility and molecular characterization. International Journal of Cancer. https://doi.org/10.1002/ijc.70454

Vancouver

Meng J, Ge L, Wang X, Yu Z, Cheng P, Yang M, et al. The 2023 FIGO staging system in uterine serous carcinoma: Exploring prognostic utility and molecular characterization. International Journal of Cancer. 2026. doi:10.1002/ijc.70454

BibTeX
@article{Meng2026,
  author = {Meng, Jiang and Ge, Li and Wang, Xiaoli and Yu, Zhicheng and Cheng, Ping and Yang, Maolin and Li, Jie and Wu, Dabao and Zhou, Ying and Zhu, Jing and Chen, Zhengzheng and Peng, Ying and Li, Yuebo and Zhao, Weidong},
  title = {The 2023 FIGO staging system in uterine serous carcinoma: Exploring prognostic utility and molecular characterization},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70454}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche